___

• Yih WY, Kratochvil FJ, Stewart JC. Intraoral minor salivary gland neoplasms: review of 213 cases. J Oral Maxillofac Surg 2005;63(6):805-10
• Regezi JA, Lloyd RV, Zarbo RJ, McClatchey KD. Minor salivary gland tumors. A histologic and immunohistochemical study. Cancer 1985; 55:108-115.
• Isacsson G, Shear M. Intraoral minor salivary gland tumors: A retrospective study of 201 cases. J Oral Pathol 1983; 12:57-62.
• Eveson JW, Cawson RA. Tumors of the minor (Oropharyngeal) salivary glands. A demographic study of 336 cases. J Oral pathol 1985; 14:500-509.
• Toida M, Shimokawa K, Makita H, Kato K, Kobayashi A, Kusunoki Y, et al.Intraoral minor salivary gland tumors. A clinic o-pathological study of 82 cases. Int J Oral Maxillofacial Surg 2005; 34:528-32.
• Sugiura R, Kuyama K, Miyake M, Wakita M, Nishiyama T, Suzuki Y, Nakamura F, Fukomuto M, Yamamato H. Intraoral minor salivary gland tumors. A retrospective study of 92 cases. Nihon University J Oral Science 2001; 27(1):10-15.
• Pires FR, Pringle GA, Almeda OP, Chen SY. Intraoral minor salivary gland tumors. A clinic-pathological study of 546 cases. Oral Oncol 2007; 43:463-70.
• Al-Rawi NH .Intraoral Minor salivary gland tumors: A clinic- pathological study of 140 cases. Iraqi Dent J 2001; 27:143-150.
• Nagel R, Laskawi A, Wahlers B, Hemmerlein I. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2 and -3 in benign and malignanat tumors of salivary gland. Histopathol 2004; 44:222-31.
• Zhang X, Wang Y, Tamamoto G, Tachikawa T. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas. Histopathology 2009; 55(3):250-260.
• Westernoff TH, Jordan RC, Regezi JA, Ramos DM, Schmidt BL. ß-6 Integrin, tenascin-C, and MMP-1 expression in salivary gland neoplasms. Oral Oncol 2005; 41:170-174.
• Mignatti P, Rifkin DB. Biology and biochemistry of proteases in tumor invasion. Physiol Rev 1993; 73:161-195.
• Stettler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 1993; 9:541-73.
• Matrisian L. The matrix degrading metalloproteinases. Bioassays 1992; 14:455-59.
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Cir Res 2003; 92:827-39.
• Stolow MA, Bauzon DD, Li J, Sedjwick T, Liang VC, Sang QA , Shi YB. Identification and characterization of a novel collagenases in Xenopus laevis: Possible roles during frog development. Mol Biol Cell 1996; 7:1471-83.
• Patterson ML, Atkinson SJ, Knauper V, Murphy G. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEB Cell 2001; 503:158-62.
• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem biophys Acta 2000; 1477:267-283.
• Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Massenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. AM J Pathol 1993; 142:359-65.
• Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001; 411:375-79.
• Haykawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting metalloproteinases-2(TIMP-2). J Cell Sci 1994:107; 2373-79.
• Kallakury BVs, Karikehalli S, Haholu A, Sheehan CE, Azumi JS, of tissue inhibitor of Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloprotenases 1 and 2 correlate with poor prognostic variable in renal cell carcinoma. Clin Cancer Res 2001; 7:3113-19.
• Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani S, Kagawa S. Prognostic value of matrix metalloproteinase-2 expression expression in bladder cancer. Cancer 1998; 82:1359-66. of metalloproteinase-2
• Gray ST, Wilkins RJ, Yun K.Interstitial collagenase gene expression in oral squamous cell carcinoma. AM J Pathol 1992; 141:301-306.